Posted by Michael Wonder on 03 Jul 2024
Inozyme Pharma announces FDA fast track designation for INZ-701 in ABCC6 deficiency
2 July 2024 - Inozyme Pharma today announced that the US FDA has granted fast track designation to INZ-701 for the treatment of ABCC6 deficiency.
The designation has been granted based on non-clinical pharmacology data and preliminary safety and efficacy data from the Company’s on-going Phase 1/2 trial of INZ-701 in adults with ABCC6 deficiency.
